Share on StockTwits

Mednax (NYSE:MD) has been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the company, AnalystRatingsNetwork.com reports. Three investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $83.40.

MD has been the subject of a number of recent research reports. Analysts at Susquehanna initiated coverage on shares of Mednax in a research note on Tuesday, July 8th. They set a “positive” rating on the stock. Separately, analysts at Dougherty & Co raised their price target on shares of Mednax from $63.00 to $66.00 in a research note on Monday, May 5th. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Mednax in a research note on Thursday, April 17th. They now have a $69.00 price target on the stock.

Mednax (NYSE:MD) opened at 56.85 on Wednesday. Mednax has a 52-week low of $47.295 and a 52-week high of $64.51. The stock’s 50-day moving average is $58.07 and its 200-day moving average is $58.27. The company has a market cap of $5.632 billion and a P/E ratio of 20.05.

Mednax (NYSE:MD) last released its earnings data on Thursday, May 1st. The company reported $0.63 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.63. The company had revenue of $566.00 million for the quarter, compared to the consensus estimate of $574.80 million. During the same quarter last year, the company posted $1.10 earnings per share. Mednax’s revenue was up 12.7% compared to the same quarter last year. Analysts expect that Mednax will post $3.16 EPS for the current fiscal year.

MEDNAX, Inc (NYSE:MD) is a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties and anesthesia care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.